Discover Tomorrow’s Treatments
Today
Clinical Trials Network (CTN) is a South African-owned and investigator-led clinical research network committed to delivering high-quality clinical trials across multiple geographic locations and therapeutic areas.
CTN combines experienced career investigators, with medical specialists in multiple disciplines enabling access to diverse patient populations through a growing network of dedicated South African specialist research sites.
Active Trials
Current research studies by therapeutic area
Dyslipidaemia (High Cholesterol) Trial
A cardiac outcome study assessing the effect of an oral PCSK9 inhibitor in participants with established cardiovascular disease or high risk for first event
Key Inclusion
- On atorvastatin ≥ 40mg or rosuvastatin ≥ 20mg or if intolerant, the highest tolerated statin plus other.
- Previous Myocardial Infarct (Heart Attack), Stroke, or surgery to restore blood flow to the legs.
- OR
- At high risk of above condition - High Risk Diabetics or evidence of atherosclerotic disease without a prior event.
Polaris Trial
An efficacy study of GLP-1 in participant with heart failure and obesity.
Key Inclusion
- BMI ≥ 30.
- NHY II-IV, stable.
- Left Ventricular Ejection Fraction (LVEF) >40% on ECHO within 12 months or at screen.
- At least 1 of the following:
- eGFR < 60 prior to screening (90 days)/ @ screen.
- Significant proteinuria prior.
- HF decompensation within 12 months:
- Hospitalisation record.
- Emergency visit requiring ivi loop diuretics.
Key Exclusion
For diabetic patients:
- Severe hypoglycaemia within last year or hypoglycaemia unawareness.
- T1DM
- Diabetic Retinopathy treated with photocoagulation, or injection within 180 days of screening.
- Multiple daily Insulin injections.
Ambience Trial
Atherosclerotic Cardiovascular Disease (ASCVD) in overweight patients.
Key Inclusion
- BMI ≥ 27.
- Age > 45.
- Established ASCVD: Myocardial infarct, Stroke, Peripheral arterial disease with documentation.
- At least 1 of the following:
- eGFR < 60 prior to screening (90 days)/ @ screen.
- UACR >30 mg/g prior to screening (90 days) @ screen.
- Medical Hx of ECG documented AF.
- HF decompensation within 12 months:
- Hospitalisation record.
- Emergency visit requiring ivi loop diuretics.
Elevate HF Trial
Heart failure in overweight patients.
Key Inclusion
- BMI > 25.
- LVEF > 40%.
- Symptomatic HF with NYHA II-IV.
- On a diuretic.
- If diabetic: HBA1C<10% without diabetic retinopathy or hypoglycaemia unawareness.
Key Exclusion
- Currently using Simvastatin.
Elevate CKD Trial
Known kidney disease.
Key Inclusion
- BMI > 23.
- On ACE or ARB treatment .
- Known reduced kidney function or proteinuria.
- Not on dialysis.
- If diabetic: HBA1C<10%, no retinopathy or hypoglycaemia unawareness.
Key Exclusion
- Currently using Simvastatin.
Cancer Observational Trial
This study does not involve any treatment.
Key Inclusion
- Diagnosis of ovarian, lung, central nervous system, or colorectal cancer in the past 8 weeks.
Obesity Trial
A Phase III research study investigating GLP-1 treatments for weight loss in people living with obesity, with or without type 2 diabetes.
Key Inclusion
- Aged 18 years or older.
- Body Mass Index (BMI) of 35.0 kg/m² or higher.
- Have a desire and commitment to lose at least 25% of their body weight.
Key Exclusion
- Current use of a GLP-1 receptor agonist.
- History of type 1 diabetes.
- Current treatment with insulin.
Severe Asthma Trial
This Phase III clinical trial is evaluating Verekitug, an investigational treatment, in adolescents and adults with severe asthma. The study will assess the effectiveness and safety of Verekitug when given alongside participants’ usual asthma treatment.
Key Inclusion
- Aged 12 to 80 years.
- Body weight of at least 40 kg.
- Diagnosed with asthma for at least 12 months.
- Currently receiving maintenance asthma treatment.
Key Exclusion
- Current tobacco smoking.
- Current use of nicotine-containing vapes or electronic cigarettes.
Site Locations
Current network of specialist research sites
- Dedicated Research facilities
- Clinical Consultation rooms
- Infusion capabilities
- Clinical Laboratories
- Secure Data Management systems
- Patient databases
- Experienced Study Coordination teams
- 4 Pharmacists
- 5 Permanent experienced Investigators
- 4 Rheumatologists
- 2 Oncologists
- Monitoring rooms for Clients
- Boardrooms with multimedia facilities
- Access to large metropolitan patient populations
- Collaboration with other specialists, including Endocrinology, Nephrology, Cardiology and Gastroenterology